Advanced Micro Devices vs Amgen, Inc. — how do they compare? Advanced Micro Devices trades at $480.7 (market cap $774.32B), while Amgen, Inc. trades at $412.21 (market cap $224.14B). The key difference: Advanced Micro Devices is far larger — about 3.5× Amgen, Inc.'s market cap, and Amgen, Inc. pays a 2.43% dividend while Advanced Micro Devices pays none. Which is the better fit depends on your goals.
| AMD | AMGN | |
|---|---|---|
Market Cap | $774.32B | $224.14B |
Sector | Technology | Health |
52-Week High | $580.91 | $417.20 |
52-Week Low | $151.14 | $271.18 |
Enterprise Value | $765.48B | $267.45B |
Dividend Yield | — | 2.43% |
Signals from Pluang's Aura AI — not financial advice
AMD trades at $474.32, down 1.87% on the day, with a bearish technical signal but strong fundamental momentum. The stock shows elevated valuation metrics (P/E 119.79, P/S 18.75) despite impressive revenue growth to $34.64B in 2025 and consistent earnings beats. Analyst consensus remains strongly bullish with a $615.11 price target, while recent news highlights AMD's positioning in the competitive AI semiconductor market.
AMD presents a growth story driven by AI and data center demand, with projected revenue reaching $41.3B in 2026. However, high valuations and intense competition from NVIDIA represent significant risks. The stock offers substantial upside to analyst targets but requires careful monitoring of execution and market share dynamics.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →